Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
A large proportion of cancer patients benefit from immune checkpoint therapy, while few studies focused on the relationship between soluble PD1 (sPD1) and soluble PDL1 (sPDL1) in serum and immune status of patients. ILC2 and M2 were confirmed to be related to immunosuppression in tumor patients. To...
Saved in:
| Main Authors: | Yumin Wu, Hui Guo, Jiawei Yue, Peng Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/9101912 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study on the efficacy of IFN-γ- and sPD-1-overexpressing BMSCs in enhancing immune effects for the treatment of lung adenocarcinoma
by: Yahui Xie, et al.
Published: (2025-03-01) -
sPD-1/sPD-L1 proteins in non-small cell lung cancer and esophageal squamous cell carcinoma
by: I. S. Stilidi, et al.
Published: (2022-10-01) -
Expression and its clinical significance of sPD-1 and sPD-L1 in patients with primary nephrotic syndrome
by: LV Zhi-an, et al.
Published: (2020-01-01) -
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
by: Santosh Kesari, et al.
Published: (2022-02-01) -
An investigation of the relationship between sPD-1, sPD-L1 and severe pneumonia patients admitted to ICU and its clinical significance
by: Zirong Gao, et al.
Published: (2025-06-01)